Home >  Registry
     
 
 Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Rheumatoid Arthritis

  • SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on anti-TNF alfa Therapy.
    Recruiting


  • A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single anti-TNF Inhibitor.
    Recruiting


  • A Study of Ocrelizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate.
    Recruiting


  • A Study of Ocrelizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to anti-TNF-alpha Therapy.
    Recruiting


  • A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate
    Recruiting


  • A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to DMARD and/or anti-TNF Therapy.
    Recruiting


  • A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis.
    Recruiting


  • A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis.
    Recruiting


  • A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single anti-TNF Inhibitor.
    Recruiting


  • SCORE Study: A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate.
    Recruiting


  • A Study of Ocrelizumab Given as a Single or Dual Infusion in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
    Recruiting


  • A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single anti-TNF Inhibitor.
    Recruiting


  • A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis.
    No longer recruiting


  • A Non-Comparative Study to Assess the Safety of MabThera (Rituximab) in Patients With Rheumatoid Arthritis.
    No longer recruiting


  • A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients with Rheumatoid Arthritis Who Have Had an Inadequate Response to anti-TNF Agents.
    No longer recruiting


  • A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to anti-TNF Therapies.
    No longer recruiting


  • A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.
    No longer recruiting


  • A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior anti-TNF Therapy.
    No longer recruiting


  • A Drug Interaction Study Between Tocilizumab, Methotrexate and Simvastatin on Patients With Rheumatoid Arthritis.
    No longer recruiting


  • A Study to Assess the Efficacy and Safety of Retreatment With MabThera (Rituximab) in Patients With Active Rheumatoid Arthritis (RA)
    No longer recruiting


  • A Study to Assess the Safety and Efficacy of Retreatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on anti-TNFalfa Therapy
    No longer recruiting


  • A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNFalfa Therapy
    No longer recruiting


  • A Study to Assess the Efficacy and Safety of MabThera (Rituximab) in Patients With Rheumatoid Arthritis
    No longer recruiting


  • A Study of Tocilizumab in Patients Completing Treatment in WA17822
    No longer recruiting


  • An Extension Study of Tocilizumab in Patients Completing Treatment in Tocilizumab Core Studies
    No longer recruiting


  • A Study of P38 Inhibitor (4) in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate Therapy
    No longer recruiting


  • A Study of Ocrelizumab in Patients With Rheumatoid Arthritis.
    No longer recruiting


  • A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis
    No longer recruiting


  • A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis
    No longer recruiting


  • A Study of Retreatment With MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA)
    No longer recruiting


  • A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA)
    No longer recruiting


  • A Study of MabThera (Rituximab) in Combination With Methotrexate in Methotrexate-Naive Patients With Rheumatoid Arthritis (RA)
    No longer recruiting


  • A Pharmacokinetic and Pharmacodynamic Study of MabThera (Rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA)
    No longer recruiting


  • A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy
    Completed


  • A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis
    Completed


  • A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis
    Completed


  • A Study of P38 Inhibitor (4) Monotherapy in Patients With Active Rheumatoid Arthritis
    Completed


  • A Quality of Life Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis.
    Completed


  • A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy.
    Completed


    		•

    © 1996-2008 F.Hoffmann-La Roche Ltd See our legal Statement